Log In
BCIQ
Print this Print this
 

LAPS Insulin 115/CA Exendin-4 Combo

Also known as: LAPS Insulin Combo

  Manage Alerts
Collapse Summary General Information
Company Hanmi Pharmaceutical Co. Ltd.
DescriptionCombination of LAPS Insulin115, a once-weekly insulin, and efpeglenatide, a long-acting exendin-4 analog
Molecular Target
Mechanism of Action 
Therapeutic Modality 
Latest Stage of DevelopmentPreclinical
Standard IndicationDiabetes
Indication DetailsDiabetes
Regulatory Designation
PartnerSanofi

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$4,340.6M

$440.6M

$3,900.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

11/05/2015

$4,340.6M

$440.6M

$3,900.0M

Get a free BioCentury trial today